Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Homology Medicines reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Homology Medicines announced earnings per share of $-0.590 on revenue of $802K. Analysts polled by Investing.com EPS of $-0.468 on revenue of $867.11K.
Homology Medicines 's are down 53.92% and is trading at $1.410 , still down 76.58% from its 52 week high of $6.02 set on Thursday, November 11, 2021.
Homology Medicines follows other major Healthcare sector earnings this month
Homology Medicines's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar